Vistagen Therapeutics, Inc. VTGN
0.19 USD 0.00 (-0.80%)
Nov 12, 2026, 12:16 PM EST
0.18 Day range 0.1901
0.16 52-week range 5.14
- YTD
- -71.77%
- 1 year
- -95.42%
News
defenseworld.net VistaGen Therapeutics (VTGN) Projected to Post Quarterly Earnings on Thursday VistaGen Therapeutics (NASDAQ: VTGN - Get Free Report) is projected to release its Q2 2027 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of…
benzinga.com Vistagen Intends To Adopt Incorporate Interim Assessments Of Fasedienol's Effect Through eDiaries, Qualitative Patient Surveys In Phase 3 Trial Design After Type C Meeting With FDA Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry, today announced a regulatory update from its recent, productive…
globenewswire.com Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder Constructive feedback from FDA clarifies potential Phase 3 development path forward Constructive feedback from FDA clarifies potential Phase 3 development path forward
benzinga.com Vistagen Therapeutics Implements 31% Workforce Reduction On October 26, 2026; Workforce Reduction Expected To Save $3.20M In Salary And Benefits Annually On October 26, 2026, Vistagen Therapeutics, Inc. (the "Company") implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen…
benzinga.com Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety Disorder Exploratory research results presented at Psych Congress 2026 in New OrleansFull poster presentation can be found on "Publications" section of Company’s websiteSOUTH SAN FRANCISCO, Calif., Sept. 24,…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics…
benzinga.com Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares…
benzinga.com Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.
benzinga.com VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses…
benzinga.com SRX Global Acquires Stake In Vistagen Therapeutics; Deal Terms Were Undisclosed The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Directors to discuss ideas on how to unlock shareholder value.
benzinga.com Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss Vistagen's Phase 3 fasedienol trial missed its main endpoint, but the company found a severe-patient signal and plans an FDA meeting.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings…
benzinga.com Nasdaq Gains Over 300 Points; Chicago PMI Falls In June US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%. Tech shares surged, real estate stocks fell. Chicago Business Barometer declined to 56.7.
benzinga.com US Stocks Mixed; Home Prices Increase 1.1% In April US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up 0.09%. Edible Garden AG up 87%, Unicycive Therapeutics down 46%.
benzinga.com Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol Did Not Achieve Its Primary Endpoint PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy, safety, and tolerability of a single dose of fasedienol in…- benzinga.com VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over…
- benzinga.com Vistagen Announces Its Data From PALISADE-3 Phase 3 Trial Of Fasedienol Demonstrates Well-Toleration, No Drug-Related Safety Concerns Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product…
- benzinga.com Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder, With Topline Results Expected In Q2 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product…
benzinga.com Vistagen Receives "Study May Proceed" Letter From FDA Under IND Application For Refisolone Nasal Spray For Treatment Of Vasomotor Symptoms Due To Menopause Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pressure on the stock.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why Applied Materials Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket 
benzinga.com Vistagen Therapeutics Earnings Report: Q3 Overview 
benzinga.com VistaGen Therapeutics Q3 EPS $(0.45) Misses $(0.44) Estimate, Sales $303.000K Miss $366.000K Estimate VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.44) by 2.74 percent. This is a 2.17 percent increase over losses…
benzinga.com Earnings Scheduled For February 12, 2026 
benzinga.com Jefferies Downgrades Vistagen Therapeutics to Hold, Lowers Price Target to $0.9 Jefferies analyst Andrew Tsai downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Buy to Hold and lowers the price target from $15 to $0.9.
benzinga.com Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Crude Oil Rises Over 1%; General Mills Earnings Top Views 
benzinga.com Dow Jumps 150 Points; Jabil Posts Upbeat Earnings - benzinga.com Vistagen Says PALISADE-3 Phase 3 Study Of Intranasal Fasedienol For Acute Treatment Of Social Anxiety Disorder Did Not Demonstrate Statistically Significant Improvement On Primary Endpoint Of Change On SUDS Study did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placeboFavorable safety and tolerability data were…
- benzinga.com Vistagen Presents Data Showing PH80's Potential As Rapid Intranasal Treatment For Menopause Hot Flashes, At The Menopause Society 2025 Annual Meeting Research supports the product candidate's non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkersVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com VistaGen Therapeutics Q2 EPS $(0.54) Misses $(0.48) Estimate, Sales $258.000K Beat $243.333K Estimate VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 13.45 percent. This is a 28.57 percent decrease over…- benzinga.com Earnings Scheduled For November 13, 2025
benzinga.com Examining the Future: VistaGen Therapeutics's Earnings Outlook - benzinga.com Vistagen Last Patient In PALISADE-3 Phase 3 Study Completes Trial For Evaluation Of Fasedienol To Treat Social Anxiety Disorder Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product…
- benzinga.com VistaGen Therapeutics Q1 EPS $(0.47) Beats $(0.50) Estimate, Sales $244.00K Miss $650.00K Estimate VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.50) by 6 percent. This is a 34.29 percent decrease over losses of…
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Insights Ahead: VistaGen Therapeutics's Quarterly Earnings
- benzinga.com Earnings Scheduled For June 17, 2025
- benzinga.com Insights into VistaGen Therapeutics's Upcoming Earnings
- benzinga.com Earnings Scheduled For February 13, 2025
- benzinga.com Earnings Scheduled For February 13, 2024 Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.
- benzinga.com Earnings Scheduled For November 9, 2023 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
- benzinga.com Why Vistagen Therapeutics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket Gainers SciSparc Ltd. (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price…
- benzinga.com Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected second-quarter financial results.